Allarity Therapeutics Inc. held its annual meeting of stockholders on June 13, 2025. During the meeting, several proposals were voted on. The election of Thomas H. Jensen as a Class III director was approved. The appointment of Wolf & Company, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. An amendment to the 2021 Equity Incentive Plan to increase the number of shares authorized for grant was not approved. An amendment to limit the liability of certain officers was also not approved. The proposal to adjourn the meeting, if necessary, was approved, though an adjournment was not required.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.